Abstract Compound EGFR mutations involving an exon 18 sensitizing variant and an exon 20 non-insertion point mutations pose a therapeutic dilemma: the former predicts TKI sensitivity, while the latter is frequently annotated as potentially resistant based solely on genomic location, given the absence of direct functional evidence. Here we describe a 66-year-old female never-smoker with advanced lung adenocarcinoma harboring an EGFR p.G719A (exon 18) and p.H773L (exon 20) compound mutation.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Xin
Contact Xin, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack